Abstract
The recent report of a high response to PARP1 inhibitors among heavily treated metastatic castration-resistant prostate cancer patients with DNA-repair defects (NEJM JW Oncol Hematol Dec 2015 and N Engl J Med 2015; 373:1697) has led to additional efforts to more fully characterize the potential role of germline DNA-repair mutations, which, although limited in unselected patients with localized prostate cancer, is undefined in advanced disease. To analyze …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
